Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medtronic InFuse for cervical spine

This article was originally published in The Gray Sheet

Executive Summary

Firm will conduct a trial of its InFuse bone graft in cervical spinal fusion after being granted an investigational device exemption from FDA, Medtronic announces Oct. 13. The bone graft will be used inside a polyetheretherketone (PEEK) polymer interbody spacer with a cervical plate. According to Medtronic, 200,000 spinal fusion procedures for the cervical spine are conducted in the U.S. each year. InFuse is approved to treat open tibia fractures and for anterior lumbar interbody fusion procedures. The firm also is pursuing approval for InFuse in posterior lumbar fusion and oral maxillofacial procedures...

You may also be interested in...

FDA panel to review Medtronic’s InFuse

Bone graft for oral maxillofacial procedures will go before agency's Dental Products Panel Nov. 9 in Gaithersburg, Md., according to the Oct. 26 Federal Register. Infuse contains the recombinant human bone morphogenetic protein rhBMP-2 - a "genetically engineered version of a naturally occurring protein ... capable of initiating bone growth," Medtronic says. InFuse also is being studied under an investigational device exemption for use in cervical spinal fusion (1"The Gray Sheet" Oct. 16, 2006, In Brief)...

RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca

Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.



FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts